Human immunodeficiency virus (HIV) reverse transcriptase activity correlates with HIV RNA load: implications for...

Area of Science:

• Virology
• Clinical Diagnostics
• Public Health

Background:

• Accurate measurement of human immunodeficiency virus type 1 (HIV-1) plasma RNA levels is crucial for patient monitoring in industrialized nations.
• Current gold-standard assays like Roche AMPLICOR (HIV RNA) are prohibitively expensive for resource-limited settings, hindering effective HIV management globally.

Purpose of the Study:

• To evaluate a less expensive reverse transcriptase (RT) enzyme activity assay as a surrogate for measuring viral burden in HIV-1 patients.
• To compare the performance of the RT assay against the established HIV RNA assay in diverse patient populations.

Main Methods:

• The study involved analyzing paired plasma samples from HIV-1 infected patients in the United States (n=29) and Cameroon (n=21).
• Reverse transcriptase (RT) enzyme activity was quantified and compared with plasma HIV RNA viral loads obtained from standard assays.

Main Results:

• RT levels showed a significant positive correlation with plasma HIV RNA viral loads in both U.S. (r=0.898) and Cameroonian (r=0.669) patient cohorts.
• The RT assay detected activity in 97% of samples with HIV viral loads exceeding 2,000 copies/ml.
• One sample with undetectable RNA viral load demonstrated detectable RT activity, suggesting potential sensitivity in low-viral-load scenarios.

Conclusions:

• The reverse transcriptase (RT) assay presents a simple, cost-effective alternative for assessing viral burden in HIV-1 patients.
• Further field studies are recommended to validate the practicality and utility of the RT assay for monitoring patients on antiretroviral therapy in resource-limited environments.